Table 2 Demographics and baseline characteristics of patients
|  | Surgery* (n = 63) | Neoadjuvant chemotherapy* (n = 32) | P value |
|---|---|---|---|
Age (year, mean ± SD) | 55.75 ± 14.34 | 56.47 ± 14.16 | 0.816 |
BMI, kg/m2 (mean ± SD) | 21.72 ± 3.50 | 21.54 ± 3.07 | 0.804 |
Gender, N% | 0.838 | ||
 Male | 40 (63.5) | 21 (65.6) |  |
 Female | 23 (36.5) | 11 (34.4) |  |
Hemoglobin (g/L) median, (IQR) | 119.0 (100.0-130.0) | 120.0 (88.8-130.8) | 0.774 |
Albumin (g/L) median, (IQR) | 37.50 (34.70-40.50) | 37.05 (33.53-39.45) | 0.529 |
Tumor location, N% | 0.224 | ||
 Splenic flexure | 12 (19.0) | 3 (9.4) |  |
 Descending | 8 (12.7) | 5 (15.6) |  |
 Sigmoid | 32 (50.8) | 13 (40.6) |  |
 Rectum | 11 (17.5) | 11 (34.4) |  |
Preoperative CEA, N% | 0.114 | ||
 Normal | 23 (39.0) | 18 (56.3) |  |
 Elevated | 36 (61.0) | 14 (43.8) |  |
ASA class, N% | 0.352 | ||
 I | 38 (60.3) | 15 (46.9) |  |
 II | 24 (38.1) | 17 (53.1) |  |
 III | 1 (1.6) | 0 (0.0) |  |
 IV | 0 (0) | 0 (0) |  |
pT status, N% | 0.018 | ||
 T1 | 0 (0) | 0 (0) |  |
 T2 | 1 (1.6) | 2 (6.3) |  |
 T3 | 29 (46.0) | 22 (68.8) |  |
 T4 | 33 (52.4) | 8 (25.0) |  |
pN stage, N% | 0.791 | ||
 N0 | 23 (36.5) | 14 (43.8) |  |
 N1 | 24 (38.1) | 9 (28.1) |  |
 N2 | 11 (17.5) | 7 (21.9) |  |